Pacira BioSciences

$52.61 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Pacira BioSciences

Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Stock Analysis

last close $52.61
1-mo return -8.6%
3-mo return -9.4%
avg daily vol. 623.77T
52-week high 80
52-week low 45.05
market cap. $2.4B
forward pe 16.9
annual div. -
roe 32.4%
ltg forecast 37.9%
dividend yield -
annual rev. $503M
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe